Group 1 - The demand for flu-related medications is rising significantly as the flu season approaches, with several stocks in the sector experiencing price surges [1] - Notable stocks that have reached their daily limit include Jindike, Peking University Medicine, and Te Yi Pharmaceutical, among others [1] - Data from Alibaba Health indicates a more than 500% week-on-week increase in the number of people purchasing antiviral flu medications, with Mabalosavir showing a remarkable over 600% increase [1] Group 2 - Experts warn that the H3N2 strain circulating this year is different from previous years, leading to lower immunity in the population and increased transmission risk [2] - The flu virus is known to undergo antigenic drift, but current strains are still within seasonal levels and do not indicate a stronger evolution of the virus [2] Group 3 - Companies are actively ensuring the supply of flu medications and vaccines in response to rising demand [3] - Dongyang Sunshine, a major supplier of Oseltamivir, reports comprehensive coverage of its products across hospitals, pharmacies, and online platforms, maintaining sufficient inventory [3] - Hualan Biological has noted a significant increase in demand for flu vaccines since October, with plans to enhance market supply and ensure timely delivery through cold chain logistics [3]

| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 湖北能源 | 000883 | 股权激励限售流通 | 31.47万 | | 亚钾国际 | 000893 | 股权激励限售流通 | 240万 | | 南方航空 | 600029 | 增发A股原股东配售上市 | 8.04亿 | | 宁波韵升 | 600366 | 增发A股法人配售上市 | 3599.9万 | | 华兰生物 | 002007 | 股权激励限售流通 | 132.43万 | | 久其软件 | 002279 | 股权激励限售流通 | 244.78万 | | 吉峰科技 | 300022 | 股权激励限售流通 | 25万 | | 海默科技 | 300084 | 股权激励限售流通 | 270.9万 | | 金禾实业 | 002597 | 股权激励限售流通 | 54.64万 | | 维力医疗 | 603309 | 股权激励限售流通 | 3.3万 | | 艾德生物 | 300685 | 股权激励限售流通 | 153.63万 | | 海晨股份 | 300873 | 增发A股原股东配售上市 | 1726 ...

1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更前次股东会决议的情形。 一、会议召开和出席情况 证券代码：002007 证券简称：华兰生物 公告编号：2025-045 华兰生物工程股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会的召开时间： 现场会议召开时间为：2025年11月17日14:30 网络投票时间：2025年11月17日。其中通过深圳证券交易所交易系统进行网络 投票的具体时间为2025年11月17日上午9:15—9:25,9:30—11:30和下午13:00— 15:00；通过深圳证券交易所互联网投票的具体时间为2025年11月17日09:15至15:00 期间的任意时间。 2、会议召开地点：公司办公楼会议室 3、会议方式：现场投票、网络投票相结合的方式 4、召集人：公司董事会 5、现场会议主持人：董事长安康先生 6、本次股东会的会议召集、召开程序符合有关法律、法规、规范性文件及《公 司章程》的有关规定。 7、会议出席情况： （1）出席会议总体情况 出席本次股东 ...

安徽承义律师事务所 关于 华兰生物工程股份有限公司 召开 2025 年第三次临时股东会的 法律意见书 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物工程股份有限公司 召开 2025 年第三次临时股东会的法律意见书 （2025）承义法字第 00247 号 致：华兰生物工程股份有限公司 经核查，本次股东会审议的提案为《关于补选第九届董事会独立董事的议案》 《关于授权关联方使用公司注册商标暨关联交易的议案》，上述提案由公司第九 届董事会提出，上述提案与会议通知一并进行了公告。本次股东会没有临时提案。 本次股东会的提案人资格及提案提出的程序均符合法律、法规、规范性文件 和公司章程的规定。 四、本次股东会的表决程序和表决结果 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等 ...

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-11-17 | 002007 | 华兰生物 | 16.42 | 150.00 | 2,463.〔机构专用 | | 中国国际金融股份 | | | | | | | | | 有限公司上海分公 ם | 11月17日，华兰生物大宗交易成交150万股，成交额2463万元，占当日总成交额的5.1%，成交价16.42 元，较市场收盘价16.42元持平。 ...

证券日报网讯华兰生物11月11日在互动平台回答投资者提问时表示，二级市场股价受宏观经济环境、市 场形势、行业发展、投资者价值判断等多方面因素影响，公司高度重视市值管理，以提升上市公司质量 为重点，持续通过完善的公司治理、高效的经营管理、持续稳定的现金分红，不断提高公司市值管理能 力及综合竞争实力，为广大投资者创造可持续的长期回报。 （文章来源：证券日报） ...

Core Viewpoint - The company emphasizes its stable cash flow and commitment to shareholder dividends, aiming to enhance long-term investment value and investor satisfaction [2] Financial Performance - For the period of January to September 2025, the company's operating revenue was 3.379 billion yuan, a decrease of 3.2% compared to the same period last year [2] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 742 million yuan, down 9.17% year-on-year [2] - The decline in revenue and net profit is primarily attributed to the postponement of vaccine sales by the company's subsidiary, with expectations of improved performance in the fourth quarter due to increased sales of flu vaccines [2]

Core Viewpoint - The company, Hualan Biological Engineering, emphasizes its leading position in the domestic influenza vaccine market, highlighting increased demand for flu vaccinations and its commitment to meeting this demand through enhanced supply capabilities [1] Group 1: Company Overview - Hualan Biological's subsidiary, Hualan Vaccine, is the largest influenza vaccine producer in China, with an annual production capacity of 100 million doses [1] - Since the launch of the first quadrivalent influenza virus split vaccine in 2018, the company has maintained a strong market presence, consistently ranking among the top in production and sales [1] Group 2: Production and Sales - As of 2025, the company has issued a total of 54 batches of influenza vaccines, including 48 batches of the quadrivalent influenza virus split vaccine [1] - The company has observed a significant increase in public awareness regarding flu vaccinations, leading to a notable rise in demand orders from disease control centers compared to the same period last year [1] Group 3: Market Response - In response to the heightened demand, the company is increasing its market supply of influenza vaccines and is committed to timely distribution through its cold chain logistics system to meet vaccination needs across the country [1]

Core Viewpoint - The company is advancing its drug development pipeline with promising clinical results for its diabetes treatment and is progressing towards regulatory approval for another product [1] Group 1: Drug Development - The recombinant Exendin-4-FC fusion protein injection is a long-acting GLP-1 receptor agonist for type 2 diabetes treatment, having successfully completed Phase I/II clinical trials with comprehensive efficacy and safety data [1] - The company is preparing to initiate Phase III clinical trials for the Exendin-4-FC fusion protein injection [1] Group 2: Regulatory Progress - The company's subsidiary, Hualan Gene Engineering Co., Ltd., submitted a marketing application for rituximab injection on November 22, 2024, which is currently under review by the CDE [1]

Core Viewpoint - The peak of influenza cases in China is expected to occur in mid to late December this year and early January next year, with the H3N2 subtype dominating the current flu activity [2]. Group 1: Industry Overview - The overall influenza activity in China is currently on the rise, with the H3N2 subtype accounting for over 95% of cases, alongside a small presence of H1N1 and B-type influenza viruses [2]. - The China Disease Control and Prevention Center has indicated a significant increase in public awareness regarding flu vaccinations since October, particularly in November, leading to a notable rise in demand orders from local disease control centers compared to the same period last year [2]. Group 2: Company Insights - Hualan Biological Engineering, through its subsidiary Hualan Vaccine Co., is the largest producer of influenza vaccines in China, with an annual production capacity of 100 million doses [2]. - The company has maintained a leading position in both production and sales of influenza vaccines since the introduction of the first quadrivalent influenza vaccine in 2018, emphasizing high-quality products [2]. - Hualan Biological has committed to high standards of vaccine quality control and stability monitoring, ensuring the provision of high-quality and competitively priced vaccine products [3].